Gilead Already Seeking Stribild Successor, Going Solo On Key HCV Combo
This article was originally published in The Pink Sheet Daily
Executive Summary
Just weeks after the apparently successful launch of its HIV “quad pill,” Gilead already is talking up a new compound with potential as part of an HIV combination therapy. And in HCV, the company is preparing a new study without partner Bristol-Myers Squibb.